Skip to content

What Award Did Vertex Pharmaceuticals’ Orphan Drug Kalydeco (Ivacaftor) For Cystic Fibrosis Win ?

October 28, 2012

       Vertex Pharmaceuticals’ orphan drug Kalydeco (Ivacaftor) for Cystic Fibrosis (CF) wins The Wall Street Journal’s 2012 Technology Innovation Award for Medicine and Biotech. Kalydeco, the first drug to treat CF, was developed by Vertex Pharmaceuticals in collaboration with the Cystic Fibrosis Foundation (CFF).  CFF provided funding support of $75 million to Vertex Pharmaceuticals’ CF program.  

         The Wall Street Journal received 536 applications from more than 24 countries. Wall Street Journal reporters and editors reviewed all entries and 172 were then forwarded to an independent panel of judges. From that group, judges chose a total of 37 winners and runners-up in 18 categories.  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: